{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-043318","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.605577+00:00","generated_at":"2026-06-17T04:02:45.211232+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS Neurosciences submits IND to FDA for Alzheimer's antibody PMN310","bullets":["IND filed for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.","PMN310 designed for high selectivity to toxic oligomers, potentially reducing ARIA risk vs other antibodies.","Company expects to become a clinical-stage company pending FDA clearance of the IND.","Preclinical data showed strong ex vivo target engagement and favorable in vitro comparison to other Aβ antibodies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-043318","json":"https://secwatch.observer/filing/0001104659-23-043318.json","markdown":"https://secwatch.observer/filing/0001104659-23-043318.md","text":"https://secwatch.observer/filing/0001104659-23-043318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465923043318/0001104659-23-043318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465923043318/tm2312175d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:02:45.211232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}